CA2786664C - Vectors and methods for transducing b cells - Google Patents
Vectors and methods for transducing b cells Download PDFInfo
- Publication number
- CA2786664C CA2786664C CA2786664A CA2786664A CA2786664C CA 2786664 C CA2786664 C CA 2786664C CA 2786664 A CA2786664 A CA 2786664A CA 2786664 A CA2786664 A CA 2786664A CA 2786664 C CA2786664 C CA 2786664C
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- interest
- nucleic acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29352210P | 2010-01-08 | 2010-01-08 | |
| US61/293,522 | 2010-01-08 | ||
| PCT/US2011/020578 WO2011085247A2 (en) | 2010-01-08 | 2011-01-07 | Vectors and methods for transducing b cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2786664A1 CA2786664A1 (en) | 2011-07-14 |
| CA2786664C true CA2786664C (en) | 2020-03-10 |
Family
ID=44306176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2786664A Active CA2786664C (en) | 2010-01-08 | 2011-01-07 | Vectors and methods for transducing b cells |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9074223B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2521789B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5873807B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2786664C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2521789T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2617749T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011085247A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104080805B (zh) * | 2011-11-07 | 2017-02-22 | 美国政府健康及人类服务部 | gp41中和性抗体及其用途 |
| ES2786253T3 (es) * | 2013-03-14 | 2020-10-09 | Immusoft Corp | Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g |
| US20160075766A1 (en) | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
| JP6568207B2 (ja) * | 2014-05-19 | 2019-08-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ヒツジb細胞を用いて抗体を産生するための方法およびその使用 |
| EP4177336A1 (en) | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| CA2981077A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| EP3417052B1 (en) * | 2016-02-16 | 2023-02-15 | Duke University | Methods for expanding and differentiating b cells for producing antibody |
| JP2020517692A (ja) * | 2017-04-27 | 2020-06-18 | イミュソフト コーポレーション | 治療剤のin vivo送達のためのB細胞およびその投薬量 |
| CN119265240A (zh) * | 2017-10-20 | 2025-01-07 | 弗莱德哈钦森癌症中心 | 用以产生被遗传修饰来表达所选抗体的b细胞的系统和方法 |
| CA3093716A1 (en) | 2018-03-16 | 2019-09-19 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
| RU2714380C1 (ru) * | 2018-12-28 | 2020-02-14 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ получения цитотоксических т-лимфоцитов, экспрессирующих химерные рецепторы |
| CA3136551A1 (en) * | 2019-04-12 | 2020-10-15 | Board Of Regents, The University Of Texas System | Methods for producing regulatory b cells and uses thereof |
| WO2021154993A1 (en) * | 2020-01-28 | 2021-08-05 | University Of Southern California | Genome engineering the human immunoglobulin locus to express recombinant binding domain molecules |
| CA3192356A1 (en) * | 2020-08-17 | 2022-02-24 | Northwestern University | B-cell based immunotherapy for the treatment of glioblastoma and other cancers |
| US20250152714A1 (en) | 2023-11-15 | 2025-05-15 | Immusoft Corporation | Migratory modified differentiated b cells for cancer therapy |
| WO2025147573A2 (en) | 2024-01-05 | 2025-07-10 | Immusoft Corporation | Glp-1 expressing modified b cells for the treatment of metabolic disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| CA2413995C (en) | 2000-06-01 | 2013-08-13 | Dnavec Research Inc. | Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity |
| WO2003068819A1 (en) * | 2001-12-22 | 2003-08-21 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
| US7632509B2 (en) * | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
| EP1975239A1 (en) | 2006-09-27 | 2008-10-01 | Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer | Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening |
| US8133727B2 (en) | 2008-11-21 | 2012-03-13 | California Institute Of Technology | In vitro human B lymphopoiesis culture system |
-
2011
- 2011-01-07 DK DK11732231.3T patent/DK2521789T3/en active
- 2011-01-07 EP EP11732231.3A patent/EP2521789B1/en active Active
- 2011-01-07 CA CA2786664A patent/CA2786664C/en active Active
- 2011-01-07 JP JP2012548181A patent/JP5873807B2/ja active Active
- 2011-01-07 US US13/520,921 patent/US9074223B2/en active Active
- 2011-01-07 WO PCT/US2011/020578 patent/WO2011085247A2/en not_active Ceased
- 2011-01-07 ES ES11732231.3T patent/ES2617749T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013516194A (ja) | 2013-05-13 |
| EP2521789A4 (en) | 2013-08-21 |
| WO2011085247A3 (en) | 2011-11-10 |
| EP2521789B1 (en) | 2016-12-14 |
| JP5873807B2 (ja) | 2016-03-01 |
| DK2521789T3 (en) | 2017-03-27 |
| WO2011085247A4 (en) | 2011-12-29 |
| EP2521789A2 (en) | 2012-11-14 |
| WO2011085247A2 (en) | 2011-07-14 |
| ES2617749T3 (es) | 2017-06-19 |
| US9074223B2 (en) | 2015-07-07 |
| CA2786664A1 (en) | 2011-07-14 |
| US20130143267A1 (en) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230081163A1 (en) | B cells for in vivo delivery of therapeutic agents | |
| US20250243459A1 (en) | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors | |
| EP2521789B1 (en) | Vectors and methods for transducing b cells | |
| WO2018201071A1 (en) | B cells for in vivo delivery of therapeutic agents and dosages thereof | |
| CA2971430C (en) | B cells for in vivo delivery of therapeutic agents | |
| HK1178934B (en) | Vectors and methods for transducing b cells | |
| HK1178934A (en) | Vectors and methods for transducing b cells | |
| HK1220230B (en) | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors | |
| HK1245834B (en) | B cells for in vivo delivery of therapeutic agents | |
| WO2025016333A1 (zh) | 一种工程化免疫细胞及其制备和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160106 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241207 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241207 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |